FRS
0.026
160%
OCT
0.045
-42.3%
CRS
0.062
138.5%
NRZ
0.002
-33.3%
AVE
0.007
133.3%
CHM
0.006
-25%
LAT
0.074
111.4%
JAV
0.003
-25%
RLL
0.004
100%
HYD
0.019
-24%
SCN
0.027
80%
DUN
0.033
-23.3%
BP8
0.005
66.7%
TFL
0.01
-23.1%
EVR
0.005
66.7%
EXR
0.034
-22.7%
RGL
0.005
66.7%
GLL
0.007
-22.2%
SLM
0.105
66.7%
OZM
0.125
-21.9%
RR1
0.013
62.5%
TMG
0.036
-21.7%
RAS
0.025
56.3%
AGH
0.02
-20%
BGE
0.03
50%
CRR
0.004
-20%
CDT
0.003
50%
EM2
0.008
-20%
TMK
0.003
50%
CVL
1.06
-19.4%
BSX
0.051
45.7%
NWM
0.013
-18.8%
VIT
0.112
41.8%
AQD
0.04
-18.4%
CMO
0.024
41.2%
BUS
0.155
-18.4%
TOR
0.1
40.8%
LOT
0.195
-17%
EXT
0.018
38.5%
PUA
0.01
-16.7%

Short Video: Arovella Therapeutics (ASX:ALA): A novel cell therapy treatment for cancers and tumours

Arovella Therapeutics (ASX:ALA) is a biotechnology company focused on developing its invariant Natural Killer T – or iNKT for short – cell therapy platform. The Company is now targeting the creation of products premised on this platform that treat blood cancers and solid tumours. Arovella Therapeutics’ lead product is ALA-101, which consists of iNKT cells modified to produce a Chimeric Antigen Receptor that targets a specific antigen found on the surface of numerous cancer types. Joining The Stock Network’s Lel Smits ahead of appearing at Australian Equities Day in Singapore is Arovella Therapeutics CEO & Managing Director Dr Michael Baker.

1. ALA-101 – iNKT cells create receptors that target antigens
The current lead product coming out of Arovella Therapeutics’ cell therapy platform is ALA-101. In layman’s language, how does it target cancers and tumours?

2. Timing of Phase 1 trials for ALA-101
A recent meeting between Arovella and the US FDA indicated that development plans to commence a Phase 1 trial of ALA-101 are progressing well. When do you expect this in-human Phase 1 trial to occur and what cancers are being targeted?

_ _ _

Subscribe to TSN’s YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1
_ _ _

Follow TSN for the latest stock news and interviews:
Twitter: https://twitter.com/thestocknet
Instagram: https://www.instagram.com/thestocknetwork/
LinkedIn: https://www.linkedin.com/company/the-stock-network/
TikTok: https://www.tiktok.com/@thestocknet?lang=en
Facebook: https://www.facebook.com/TheStockNet/

_ _ _
Connect with our host Lel Smits online – @LelSmits
– Twitter / X: https://twitter.com/lelsmits
– Instagram: https://www.instagram.com/lelsmits/
– LinkedIn: https://www.linkedin.com/in/leldesmits/
– TikTok: https://www.tiktok.com/@lelsmits?lang=en
– Facebook: https://m.facebook.com/lelsmits/
– Threads: https://www.threads.net/@lelsmits
_ _ _

Disclaimer
The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss.

This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer.

_ _ _

Visit TSN’s website to sign up for regular stock updates: http://www.thestocknetwork.com.au
_ _ _